Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Enterprise Value (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Enterprise Value for 12 consecutive years, with -$140.1 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value rose 11.41% year-over-year to -$140.1 million; the TTM value through Mar 2026 reached -$140.1 million, up 11.41%, while the annual FY2025 figure was -$154.5 million, 5.83% up from the prior year.
  • Enterprise Value hit -$140.1 million in Q1 2026 for Syndax Pharmaceuticals, up from -$154.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$63.3 million in Q1 2023 and bottomed at -$570.7 million in Q4 2023.
  • Average Enterprise Value over 5 years is -$234.6 million, with a median of -$154.5 million recorded in 2025.
  • On a YoY basis, Enterprise Value climbed as much as 84.09% in 2023 and fell as far as 666.34% in 2023.
  • Syndax Pharmaceuticals' Enterprise Value stood at -$74.5 million in 2022, then tumbled by 666.34% to -$570.7 million in 2023, then soared by 71.24% to -$164.1 million in 2024, then increased by 5.83% to -$154.5 million in 2025, then rose by 9.37% to -$140.1 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$140.1 million, -$154.5 million, and -$135.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.